Shire PLC (SHPG) Given a $198.00 Price Target by Leerink Swann Analysts
Shire PLC (NASDAQ:SHPG) received a $198.00 price objective from investment analysts at Leerink Swann in a report issued on Monday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Leerink Swann’s target price would suggest a potential upside of 7.05% from the company’s current price.
SHPG has been the topic of a number of other research reports. HSBC cut shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Monday, September 26th. Shore Capital restated a “buy” rating on shares of Shire PLC in a research note on Tuesday, August 30th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research note on Tuesday, September 27th. Jefferies Group restated a “buy” rating and set a $262.00 target price on shares of Shire PLC in a research note on Tuesday, September 20th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a research note on Monday, October 24th. Four investment analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $222.06.
Shire PLC (NASDAQ:SHPG) opened at 184.96 on Monday. Shire PLC has a 52 week low of $147.60 and a 52 week high of $219.52. The stock’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.04. The business had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The company’s revenue was up 108.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.24 EPS. Analysts predict that Shire PLC will post $12.96 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Jennison Associates LLC boosted its stake in shares of Shire PLC by 13.2% in the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock valued at $1,526,765,000 after buying an additional 968,101 shares during the last quarter. FMR LLC boosted its stake in shares of Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock valued at $490,297,000 after buying an additional 1,237,100 shares during the last quarter. Lone Pine Capital LLC acquired a new stake in shares of Shire PLC during the second quarter valued at $465,566,000. Capital World Investors acquired a new stake in shares of Shire PLC during the second quarter valued at $285,568,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $278,421,000. 24.62% of the stock is owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.